Accessibility Menu
Pure Bioscience logo

Pure Bioscience(OTC) PURE

Current Price$0.08
Market Cap$8.82MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1996)-100%
5 Year-84%
1 Year-4%
1 Month-3%
Pure Bioscience last closing stock price
MetricPriceDate
Last closeUSD 0.072026-07-23
Pure Bioscience stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+21.94%USD 0.062026-07-16
1 month-3.14%USD 0.072026-06-23
3 month-0.74%USD 0.072026-04-24
Year to date+61.43%USD 0.042025-12-31
1 year-4.24%USD 0.072025-07-23
3 year-22.78%USD 0.092023-07-24
5 year-84.4%USD 0.432021-07-23
Since inception-99.87%USD 50.981996-08-08

Pure Bioscience Financials at a Glance

Market Cap

$8.82MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$2.42M

Net Income (TTM)

-$2.21M

EPS (TTM)

-$0.02

P/E Ratio

-3.42

Dividend

$0.00

Beta (Volatility)

0.22 (Low)

Price

$0.08

Volume

21,102

Open

$0.07

Previous Close

$0.07

Daily Range

$0.07 - $0.08

52-Week Range

$0.04 - $0.14

Estimated Earnings Date

Jun 16, 2026

PURE News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Pure Bioscience

PUR Bioscience makes cleaning and disinfecting products for food and public spaces. Its main products help restaurants and food processors keep surfaces and equipment safe. These solutions aim to reduce germs and support hygiene in daily operations.

Germ-Busting Lineup: What’s on the PURE Menu?

  • PURE Hard Surface (95.7% of Q3 2025 sales): Disinfectant for food contact surfaces, used by restaurants and food processors.
  • SILVÉRION (4.3% of Q3 2025 sales): Antimicrobial ingredient for personal care and cleaning products, sold to manufacturers.
  • PURE Control: Processing aid for fresh produce and raw poultry, used in food production.
  • PURE Multi-Purpose Cleaners: Concentrates for cleaning floors, glass, and equipment in commercial settings.
  • Axen30 and Axenohl: Hard surface disinfectants and antimicrobial ingredients for other cleaning product makers.

Growth Spurts and Strategic Moves

  • Expanded U.S. distribution network to reach more food industry customers (2023–2025).
  • Formed partnerships for regulatory approvals and international market entry (ongoing since 2023).
  • Developed new SDC-based products to address food safety and hygiene (2023–2025).
  • No major acquisitions or global market launches reported in the last two years.

Why PURE Stands Out (Without the Hype)

PUR uses a patented silver-based technology for broad, non-toxic germ control. Its products are registered with U.S. and Canadian regulators, supporting use in food and public settings. The company focuses on food safety, hygiene, and regulatory compliance for its customers.

Five Things You Need to Know

  • Revenue was $491,000 in Q3 2025, up 11.3% from Q3 2024.
  • PURE Hard Surface made up 95.7% of Q3 2025 product sales.
  • Net loss was $580,000 in Q3 2025, improving 32.3% from Q3 2024.
  • All sales in Q3 2025 were U.S.-based; no international revenue reported.
  • Cash used in operations was $1.56 million for nine months ended April 2025.

Bottom Line

PUR focuses on antimicrobial products for food safety and hygiene, using patented silver technology. The company faces ongoing financial challenges but continues to develop and distribute specialized cleaning solutions.

AI Generated • Apr 16, 2026

Industry

Household Products

Sector

Consumer Staples

Employees

12

CEO

Robert F. Bartlett

Website

www.purebio.com

Headquarters

El Cajon, CA 92019, US

PURE Financials

Key Financial Metrics (TTM)

Gross Margin

53803.55%

Operating Margin

-79.11%

Net Income Margin

-91.04%

Return on Equity

38.73%

Return on Capital

N/A

Return on Assets

-141.53%

Earnings Yield

-29.24%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$8.82MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

130.02M

Volume

21.10K

Avg. Volume

25.65K

Financials (TTM)

Gross Profit

$1.30B

Operating Income

-$1.92M

EBITDA

$185.00K

Operating Cash Flow

-$1.78M

Capital Expenditure

$0.00

Free Cash Flow

-$1.78M

Cash & ST Invst.

$983.00K

Total Debt

$6.50M

Pure Bioscience Performance Analysis

Pure Bioscience annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-07-31USD 1,853,000-52.8%
20232023-07-31USD 1,877,0001.3%
20242024-07-31USD 1,963,0004.6%
20252025-07-31USD 2,202,00012.2%
Pure Bioscience sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42025-07-3155.6%
Q12025-10-31-7.3%
Q22026-01-31-37.3%
Q32026-04-3014.0%
Pure Bioscience annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-07-31USD -0.0447.7%
20232023-07-31USD -0.04-9.4%
20242024-07-31USD -0.03-15.7%
20252025-07-31USD -0.02-28.7%
Pure Bioscience sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42025-07-3142.3%
Q12025-10-31-36.7%
Q22026-01-31-70.7%
Q32026-04-3020.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2026YOY CHG

Revenue

$506.00K

+3.1%

Gross Profit

$269.00K

-4.9%

Gross Margin

53.16%

N/A

Market Cap

$8.82MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$801.38K

N/A

Employees

11

N/A

Net Income

-$624.00K

-7.6%

EBITDA

-$518.00K

-3.4%

Quarterly Fundamentals

Name
Q3 2026YOY CHG

Total Cash

$983.00K

+82.0%

Total Debt

$6.50M

+32.6%

Accounts Receivable

$242.00K

-15.7%

Inventory

$232.00K

+77.1%

Long Term Debt

$3.74M

-23.6%

Short Term Debt

$2.75M

N/A

Return on Assets

-1.42%

N/A

Return on Invested Capital

91.41%

N/A

Free Cash Flow

-$468.00K

+8.6%

Operating Cash Flow

-$468.00K

+8.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
EXDWExceed World, Inc.
$0.29+0.00%
DQWSDSwiss, Inc.
$0.03+0.00%
CAWWCCA Industries, Inc.
$0.45-9.09%
HIGRHi-Great Group Holding Company
$0.03-0.34%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.22-0.07%
ONDSOndas
$7.87-0.01%
NOKNokia
$9.08-0.07%
TQQQProShares Trust - ProShares UltraPro Qqq
$63.73-0.04%

Questions About PURE

What is the current price of Pure Bioscience?

Pure Bioscience is trading at $0.08 per share.

What is the 52-week range for Pure Bioscience?

Over the past 52 weeks, Pure Bioscience has traded between $0.04 and $0.14.

How much debt does Pure Bioscience have?

As of the most recent reporting period, Pure Bioscience reported total debt of $6.50M.

How much cash does Pure Bioscience have on hand?

Pure Bioscience reported $1.06M in cash and cash equivalents in its most recent financial results.

What is Pure Bioscience’s dividend yield?

Pure Bioscience does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services